Mizuho raised the firm’s price target on Intra-Cellular to $74 from $66 and keeps a Buy rating on the shares. The analyst believes the Phase 3 mixed features data provide a positive read-through to the drug’s prospects in major depressive disorder, a larger commercial opportunity for which a Phase 3 program is underway. The firm increased its probability of success assumption in major depressive disorder to 65% from 40% on increased confidence in Caplyta.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on ITCI:
- Intra-Cellular price target raised to $98 from $93 at Canaccord
- Needham says positive move in Intra-Cellular stock makes sense
- ITCI Gains on Promising Results in Depression Treatment
- Intra-Cellular: Study 403 of lumateperone met primary endpoint for MDD
- Intra-Cellular Therapies Announces Positive Topline Results from Study 403 Evaluating Lumateperone as Monotherapy in Patients with Major Depressive Disorder with Mixed Features and Bipolar Depression with Mixed Features
